<DOC>
	<DOC>NCT01935154</DOC>
	<brief_summary>Patients with stage IV or recurrent stage I-III NSCLC with documented disease control (objective response or stable disease) within 3 weeks after platinum based 1st line chemotherapy; only HLA-A*0201 positive patients with TERT expressing tumors will be included. The objective of the trial is survival rate at 12 months.</brief_summary>
	<brief_title>Efficacy Study of Vx001 Vaccine in NSCLC Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Main 1. Male or female â‰¥18 years of age; 2. Documented stage IV NSCLC as defined by IASLC Lung Cancer Staging Project (7th edition) or recurrent stage IIII disease at least 6 months after resection or after the end of adjuvant chemotherapy or after standard locoregional treatment as defined by the American College of Chest Physicians; 3. Patients treated with 4 cycles platinum based 1st line chemotherapy as defined by the American College of Chest Physicians (i.e. radiotherapy are not allowed except palliative radiotherapy of bone metastasis); 4. Documented HLAA*0201 positivity, as determined by a local laboratory; 5. TERTpositive NSCLC, as assessed by a central laboratory; for this, availability of adequate tissue biopsy from the primary tumor, lymph nodes or distant metastases is a prerequisite; 6. CR, PR, or SD according to RECIST 1.1 criteria after the completion of platinumbased firstline chemotherapy; 7. ECOG performance status 0, 1; Main 1. Mixed small cell and NSCLC histologies; 2. Patients with stage IV or recurrent NSCLC who have been previously treated with therapy other than platinumbased firstline chemotherapy; 3. Prior treatment with cancer vaccines; 4. Prior treatment with immunotherapy (e.g., interferons, interleukins, TNF, or biological response modifiers, such as GMCSF etc) within four weeks prior to randomization; 5. Prior treatment with hormone (including corticosteroids) within 2 weeks prior to randomization; 6. Prior treatment with any investigational drugs, within 4 weeks prior to randomization; 7. Patients with brain metastases;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Vaccine</keyword>
</DOC>